Precigen’s (PGEN) “Buy” Rating Reaffirmed at HC Wainwright

Precigen (NASDAQ:PGEN)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $4.00. HC Wainwright’s price target suggests a potential upside of 430.97% from the stock’s previous close.

Separately, JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $7.00.

Precigen Stock Performance

NASDAQ:PGEN opened at $1.13 on Thursday. The company has a market capitalization of $330.94 million, a PE ratio of -2.05 and a beta of 1.65. The company has a 50 day simple moving average of $0.92 and a two-hundred day simple moving average of $1.06. Precigen has a fifty-two week low of $0.65 and a fifty-two week high of $1.93.

Institutional Trading of Precigen

Several large investors have recently modified their holdings of PGEN. State Street Corp lifted its holdings in shares of Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after purchasing an additional 29,253 shares in the last quarter. Iridian Asset Management LLC CT increased its holdings in Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after acquiring an additional 1,706,815 shares during the last quarter. Geode Capital Management LLC increased its holdings in Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after acquiring an additional 149,829 shares during the last quarter. Stifel Financial Corp grew its holdings in Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares in the last quarter. Finally, Barclays PLC grew its holdings in Precigen by 190.4% during the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 124,141 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.